se ha leído el artículo
array:24 [ "pii" => "S1578219011000412" "issn" => "15782190" "doi" => "10.1016/j.adengl.2011.03.003" "estado" => "S300" "fechaPublicacion" => "2011-09-01" "aid" => "372" "copyright" => "Elsevier España, S.L. and AEDV" "copyrightAnyo" => "2010" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2011;102:487-97" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 8107 "formatos" => array:3 [ "EPUB" => 42 "HTML" => 6333 "PDF" => 1732 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731011001384" "issn" => "00017310" "doi" => "10.1016/j.ad.2011.03.002" "estado" => "S300" "fechaPublicacion" => "2011-09-01" "aid" => "372" "copyright" => "Elsevier España, S.L. y AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2011;102:487-97" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 9267 "formatos" => array:3 [ "EPUB" => 1 "HTML" => 6527 "PDF" => 2739 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>" "titulo" => "Conectivopatías y psoriasis" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "487" "paginaFinal" => "497" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Connective Tissue Diseases and Psoriasis" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1736 "Ancho" => 2403 "Tamanyo" => 188868 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">La diferenciación del linfocito T colaborador (Th) puede realizarse en tres líneas diferentes (Th1, Th2, Th17) según las diferentes citocinas que lo estimulen. En la diferenciación del linfocito Th17 intervienen varias citocinas; el TGF-α y la IL-6 son los principales encargados de la diferenciación a Th17, mientras que la IL-23 lo es de la supervivencia y proliferación del linfocito. Entre las múltiples citocinas secretadas por el linfocito Th17 la IL-21 ejerce un papel de retroalimentación positiva.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Cuesta-Montero, I. Belinchón" "autores" => array:2 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Cuesta-Montero" ] 1 => array:2 [ "nombre" => "I." "apellidos" => "Belinchón" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219011000412" "doi" => "10.1016/j.adengl.2011.03.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219011000412?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731011001384?idApp=UINPBA000044" "url" => "/00017310/0000010200000007/v1_201304241332/S0001731011001384/v1_201304241332/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219011000424" "issn" => "15782190" "doi" => "10.1016/j.adengl.2011.03.004" "estado" => "S300" "fechaPublicacion" => "2011-09-01" "aid" => "374" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2011;102:498-504" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3580 "formatos" => array:3 [ "EPUB" => 46 "HTML" => 2800 "PDF" => 734 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Novelties in Dermatology</span>" "titulo" => "Role of Chemokines in Melanoma Progression" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "498" "paginaFinal" => "504" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Papel de las quimiocinas en la progresión del melanoma" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2424 "Ancho" => 2500 "Tamanyo" => 262194 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Involvement of chemokines and their receptors in selective metastasis in patients with cutaneous melanoma. Black arrows indicate well-characterized interactions between chemokines and their receptors; gray arrows indicate potential associations that remain to be fully characterized; curved arrows indicate the autologous production of chemokines (ligands) by the tumor cells leading to autocrine effects. CNS indicates central nervous system.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "C. Monteagudo, A. Pellín-Carcelén, J.M. Martín, D. Ramos" "autores" => array:4 [ 0 => array:2 [ "nombre" => "C." "apellidos" => "Monteagudo" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Pellín-Carcelén" ] 2 => array:2 [ "nombre" => "J.M." "apellidos" => "Martín" ] 3 => array:2 [ "nombre" => "D." "apellidos" => "Ramos" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731011001402" "doi" => "10.1016/j.ad.2011.03.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731011001402?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219011000424?idApp=UINPBA000044" "url" => "/15782190/0000010200000007/v1_201304241231/S1578219011000424/v1_201304241231/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219011000448" "issn" => "15782190" "doi" => "10.1016/j.adengl.2011.04.001" "estado" => "S300" "fechaPublicacion" => "2011-09-01" "aid" => "393" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2011;102:484-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3045 "formatos" => array:3 [ "EPUB" => 42 "HTML" => 2196 "PDF" => 807 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Opinion Article</span>" "titulo" => "Past, Present, and Future of Propranolol for Hemangiomas of Infancy" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "484" "paginaFinal" => "486" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Hemangiomas de la infancia: pasado, presente y futuro del tratamiento con propranolol" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "E. Baselga" "autores" => array:1 [ 0 => array:2 [ "nombre" => "E." "apellidos" => "Baselga" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S000173101100192X" "doi" => "10.1016/j.ad.2011.04.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101100192X?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219011000448?idApp=UINPBA000044" "url" => "/15782190/0000010200000007/v1_201304241231/S1578219011000448/v1_201304241231/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "Connective Tissue Diseases and Psoriasis" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "487" "paginaFinal" => "497" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "L. Cuesta-Montero, I. Belinchón" "autores" => array:2 [ 0 => array:4 [ "nombre" => "L." "apellidos" => "Cuesta-Montero" "email" => array:1 [ 0 => "lcuestamontero@hotmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "I." "apellidos" => "Belinchón" ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Sección de Dermatología, Hospital General Universitario de Alicante, Alicante, Spain" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Conectivopatías y psoriasis" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1736 "Ancho" => 2403 "Tamanyo" => 196687 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Naive T helper (T<span class="elsevierStyleInf">H</span>) cells differentiate into 3 different subsets (T<span class="elsevierStyleInf">H</span>1,T<span class="elsevierStyleInf">H</span>2,and T<span class="elsevierStyleInf">H</span>17) depending on the cytokine stimuli they receive. Transforming growth factor (TGF) β and interleukin (IL) 6 are the primary mediators of differentiation into T<span class="elsevierStyleInf">H</span>17 cells, while IL-23 contributes to the survival and proliferation of these cells. Among the many cytokines secreted by T<span class="elsevierStyleInf">H</span>17 cells, IL-21 intervenes in a positive feedback loop. IFN indicates interferon; TNF, tumor necrosis factor.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">In practice, we often encounter patients with connective tissue diseases or psoriasis. However, very few patients present with both conditions and in such cases the signs and symptoms differ from those seen in patients with either disease alone. Most reports of this combination in the literature refer to single cases or small series and no controlled trials or review articles exist. Consequently, we considered that it would be interesting to review the association from the point of view of clinical features, therapeutic management, and their shared common pathogenesis.</p><p id="par0010" class="elsevierStylePara elsevierViewall">Connective tissue diseases are a heterogeneous group of acquired and hereditary disorders characterized by abnormal function or structure of one or more of the elements of connective tissue, such as collagen, elastin, or the mucopolysaccharides. The group is one of the 10 categories of rheumatic diseases in the American College of Rheumatology classification (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>) and it includes entities such as lupus erythematosus, rheumatoid arthritis, Felty syndrome, juvenile chronic arthritis, adult Still disease, scleroderma, fasciitis, polymyositis, vasculitis, Sjögren syndrome, and polymyalgia rheumatica.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> This review deals with the coexistence of psoriasis with systemic lupus erythematosus (SLE), dermatomyositis (DM), scleroderma, and rheumatoid arthritis (RA).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Psoriasis is a common inflammatory disease with an estimated mean prevalence worldwide of around 2%, although according to the Epiderma study the prevalence in Spain is slightly lower (1.4%).<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> Despite its prevalence in the general population, there are only a few published cases of concomitant psoriasis and connective tissue disease. Although the pathogenesis of psoriasis has not been clearly established, in patients who present with this combination it is believed that there may be a shared autoimmune base, which we will discuss below<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,4</span></a>; most connective tissue diseases are autoimmune in nature.</p><p id="par0020" class="elsevierStylePara elsevierViewall">While the prevalence of rheumatic diseases is high in Spain (23% according to the EPISER study<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a>), the prevalences of RA and SLE are much lower. That study estimated that there are around 500 cases of RA per 100<span class="elsevierStyleHsp" style=""></span>000 population in Spain (worldwide prevalence ranges from 300 to 1200 cases per 100 000 population<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a>) and around 9 cases of SLE per 100 000 population. Although the epidemiologic data available on connective tissue diseases is scant, we indicate below the data obtained from several Spanish epidemiologic studies. In 2003, López et al<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> reported a prevalence of 34.1 cases and an incidence of 2.2 cases per 100 000 population for SLE. In a study published in 2007, Vargas-Leguás et al<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> reported an incidence in Spain of 4.9 cases per million population per year for DM. Although the data on the prevalence of scleroderma in Spain is scant, a study published by Villaverde-Hueso et al<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> in 2007 reported a prevalence of 0.23-2.58 cases per 10 000 population.</p><p id="par0025" class="elsevierStylePara elsevierViewall">These findings indicate a low prevalence of connective tissue diseases in the general population, explaining why there are few series in the literature and why most published reports refer to single cases. We will describe each of these 4 entities separately, covering both pathogenesis and etiology.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Immunopathogenesis of Psoriasis and Autoimmune Connective Tissue Diseases</span><p id="par0030" class="elsevierStylePara elsevierViewall">The etiology and pathogenesis of psoriasis are not yet clearly understood, but the condition is thought to be related to a polygenic predisposition and a number of environmental trigger factors, such as stress, trauma, infection, and drugs.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9,10</span></a> While the model of inheritance for psoriasis is quite complex,<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> a genetic component has been established by studies that have demonstrated a risk of both twins having psoriasis that is 2 or 3 times greater in monozygotic than in dizygotic twins.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> Several genes that confer increased susceptibility to psoriasis have recently been identified, among which the <span class="elsevierStyleItalic">PSORS</span> gene complex (1 to 9) is of particular interest.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> The principal genetic determinant is <span class="elsevierStyleItalic">PSORS1</span>, a susceptibility locus that lies within the major histocompatibility complex on chromosome 6p and is thought to account for up to 50% of the genetic transmission of psoriasis.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> The various clinical forms of psoriasis are related to different genetic expressions, at least in the case of <span class="elsevierStyleItalic">PSORS1</span>.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15,16</span></a> Alterations in interleukin (IL) 12B and in the IL-23 receptor that appear to be risk indicators in psoriasis have also been identified.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> The following are other genes that appear to play a role: <span class="elsevierStyleItalic">CDKAL1</span> located on chromosome 6p, which is also implicated in Crohn disease and type 2 diabetes mellitus<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a>; the zinc-finger 313 gene (<span class="elsevierStyleItalic">ZNF313</span>); and the <span class="elsevierStyleItalic">PTPN22</span> gene present in type 1 diabetes mellitus, idiopathic juvenile arthritis, SLE, and RA.<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">11,19</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">Psoriasis shares both immunologic and genetic risk factors with other autoimmune diseases such as the connective tissue diseases RA and SLE. Previously, CD4 helper T (T<span class="elsevierStyleInf">H</span>) 1 cells were considered to be the most important cells in the pathogenesis of these diseases, but greater importance is now given to the role of T<span class="elsevierStyleInf">H</span>17 cells,<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> a novel CD4 T effector cell that plays an important role in many autoimmune diseases.<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">21,22</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">Until a few years ago, only 2 types of such cells were known (T<span class="elsevierStyleInf">H</span>1 and T<span class="elsevierStyleInf">H</span>2), but a third type—T<span class="elsevierStyleInf">H</span>17—has now been identified. T<span class="elsevierStyleInf">H</span>1 cells intervene in the development of CD8 cells and T<span class="elsevierStyleInf">H</span>2 cells are responsible for the antibody-mediated immune response, while T<span class="elsevierStyleInf">H</span>17 cells are implicated in the autoimmune inflammatory response.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> Naive T<span class="elsevierStyleInf">H</span> cells differentiate into specific types depending on the stimulus they receive (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a> Differentiation into T<span class="elsevierStyleInf">H</span>17 cells is mediated primarily by transforming growth factor-β, while IL-23 contributes to the survival and proliferation of these cells. IL-23 concentration is elevated in psoriasis lesions and decreases when the lesions respond to treatment, revealing a direct correlation between overproduction of IL-23 and active psoriasis. It has been suggested that the IL-23/T<span class="elsevierStyleInf">H</span>17 axis may play a fundamental role in the pathogenesis of psoriasis.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a></p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0045" class="elsevierStylePara elsevierViewall">The main cytokines secreted by T<span class="elsevierStyleInf">H</span>17 are IL-6, IL-17, IL-21, and IL-22; the last 2 induce keratinocyte hyperproliferation.<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">23,25</span></a> Moreover, it is thought that IL-21 may also act as a feedback mechanism stimulating production of T<span class="elsevierStyleInf">H</span>17 cells. The most recent theories posit that therapies targeting IL-23 alone would be sufficient to improve psoriasis, but some authors have suggested that neutralizing IL-21 in vivo by means of soluble receptors or monoclonal antibodies could be a useful tool in the treatment of psoriasis.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Thus, current theories postulate that in a genetically predisposed individual the pathogenesis of psoriasis would require an unknown stimulus to act on epidermal keratinocytes to produce a number of chemical mediators, such as tumor necrosis factor (TNF) α, interferon(IFN) γ, and IFN-α (the key cytokines in psoriasis); these mediators would in turn activate plasmacytoid and myeloid dendritic cells. Once activated, these cells would induce the differentiation of naive T cells into T<span class="elsevierStyleInf">H</span>1 and T<span class="elsevierStyleInf">H</span>17 cells, which would then migrate to the skin, acting as antigen-presenting cells and releasing cytokines, such as TNF-α, IFN-γ, IL-23, IL-22, and IL-17. These cytokines would induce the proliferation of keratinocytes and alter their maturation, giving rise to the epidermal hyperproliferation which, together with inflammatory T cell infiltration, constitutes the fundamental basis of psoriasis lesions.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">This etiologic and pathogenic complexity is not exclusive to psoriasis and, in fact, it would appear that T<span class="elsevierStyleInf">H</span>17 cells, as well as IL-17 and IL-23, are also implicated in SLE, although the role of these cytokines in humans is poorly understood because most studies to date have been carried out in mice. In fact, elevated T<span class="elsevierStyleInf">H</span>17-cell serum concentrations have been observed in some patients with SLE; IL-17 and IL-23, which may contribute to the renal damage, have also been detected in the kidneys of patients with lupus nephritis.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> Since reductions in the production of IL-17 in mice have been correlated with clinical improvement, it has been proposed that anti-IL-17 therapy could be useful in the treatment of patients with elevated serum levels of this cytokine.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> IL-21 levels are also elevated in the serum of these patients, although in this case there is no apparent correlation with disease severity.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> Polymorphisms have recently been identified within the chromosome 4q27 region, which harbors the genes that code for IL-2 and IL-21. These variants are associated with SLE, RA, psoriasis, ulcerative colitis, diabetes, and asthma,<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">28–32</span></a> an indication that these diseases may share a common genetic factor.</p><p id="par0060" class="elsevierStylePara elsevierViewall">T<span class="elsevierStyleInf">H</span>17 cells also appear to play an important role in the development of RA. In both mice and humans, elevated levels of IL-17<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a> and IL-21<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">34</span></a> in serum and synovial fluid have been seen to correlate with joint damage, and in fact, mice with an IL-17 deficit do not develop RA. In RA, as in psoriasis, IL-23 has been identified as the main target for blockade. Moreover, blockade of Il-21 has also been proposed as a way to improve disease in RA, and the effectiveness of this mechanism has been demonstrated in animal models.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">35</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">What is clear is that the immune response in these diseases is very complex and involves a large number of regulating mechanisms, including the key role played by T<span class="elsevierStyleInf">H</span>1 cells and their cytokines IFN-γ and IFN-α, which act by inhibiting or downregulating the expression of IL-17 and T<span class="elsevierStyleInf">H</span>17 differentiation in vitro and in vivo.<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">36</span></a> An understanding of these mechanisms allows us to understand in greater detail the complexity of these diseases and the relationship between them. Moreover, as we have briefly noted above, future therapies for many of these diseases, whether they occur in isolation or concomitantly, will be based on the control of these regulation mechanisms.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Systemic Lupus Erythematosus and Psoriasis</span><p id="par0070" class="elsevierStylePara elsevierViewall">SLE is a rheumatic autoimmune disease of unknown etiology characterized by a set of clinical signs and symptoms associated with the presence of autoantibodies. Although its pathogenesis is poorly understood, a number of contributing factors have been identified, the most important of which is the production of autoantibodies. These autoantibodies are thought to be the key in the pathogenesis of SLE because they can interfere directly with cell function or act through immune complexes. They are produced through polyclonal B cell activation or autoantigen-directed immune stimulation.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> Genetic, environmental, and hormonal factors have also been described.</p><p id="par0075" class="elsevierStylePara elsevierViewall">Diagnosis of SLE is based on clinical and analytic criteria that were first described in 1982 by the American College of Rheumatology and later revised in 1997 (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0080" class="elsevierStylePara elsevierViewall">SLE is associated with various autoimmune diseases, such as RA, Sjögren disease, Hodgkin disease, and Crohn disease.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,38</span></a> However, the association of SLE and psoriasis is very rare. The mechanisms involved in this association are poorly understood, but it is thought that there must be a common immunologic basis.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> T cells play a primary role in the pathogenesis of psoriasis while B cells appear to be central in SLE, giving rise to the view that superantigens might be the common mediator.<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">39–41</span></a> However, it is now known that alterations in the T<span class="elsevierStyleInf">H</span>17 cell pathway occur in both diseases.</p><p id="par0085" class="elsevierStylePara elsevierViewall">In 1927, O’Leary<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">42</span></a> published one of the first case reports of concomitant psoriasis and SLE. Since then, most publications have referred to isolated cases or small series.<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">39,43–45</span></a> The largest series was published in 1996 by Zalla and Muller,<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">46</span></a> who studied 9420 patients with psoriasis. They found that psoriasis and SLE occurred together in 0.69% of patients with psoriasis and in 1.1% of patients with SLE. Their findings differ only slightly from those of Dubois et al,<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">47</span></a> who reported concomitant psoriasis in 0.6% of 520 patients with discoid SLE. There is no established pattern of onset when both are present: psoriasis develops first in some cases and lupus erythematosus (LE) in others. Onset can even be simultaneous, although this occurs less frequently.<a class="elsevierStyleCrossRefs" href="#bib0215"><span class="elsevierStyleSup">43,46</span></a> As can be expected in view of the higher incidence of LE in women, the coexistence of psoriasis and LE is also more common in women, while the association of drug-induced lupus and psoriasis affects both sexes equally.<a class="elsevierStyleCrossRefs" href="#bib0215"><span class="elsevierStyleSup">43,46</span></a> The characteristics of psoriasis in Zalla and Muller's patients with LE were similar to those in patients with psoriasis alone, and the most common clinical picture included plaques and limb involvement. These authors did, however, report a higher risk of erythroderma in patients with LE. A case of linear psoriasis—a rare form of the disease— was reported in a patient with SLE following a flare episode with neurologic manifestations.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a> The distribution of the different clinical forms of LE in patients who also have psoriasis has been reported to be first SLE, then discoid LE, and finally drug-induced lupus.<a class="elsevierStyleCrossRefs" href="#bib0215"><span class="elsevierStyleSup">43,46</span></a> The same sources also noted that the manifestations of LE occurred later in patients with psoriasis and that photosensitivity was more frequent.</p><p id="par0090" class="elsevierStylePara elsevierViewall">A controversial aspect of the SLE-psoriasis association is whether or not specific laboratory markers are present. In 1993, Kulick et al<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">48</span></a> studied a series of 4 patients with coexistent LE and psoriasis and 24 with psoriasis alone. The 4 patients with the combination all presented the anti-Ro antibody while the 24 controls did not. These authors also described the potential severity of photosensitive reactions in patients with this combination, which are probably linked to the anti-Ro antibody. This would suggest that that the anti-Ro antibody may be a marker for the association between psoriasis and LE. However, Hays et al<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">49</span></a> later reported on 4 patients with LE and psoriasis in whom the anti-Ro antibody was not found. The current view is that no specific serologic marker exists for the psoriasis-SLE overlap. Most authors recommend that a detailed medical history include any history of photosensitivity, a symptom that occurs in almost 50% of these patients, and that patients be tested for antinuclear antibodies, anti-double stranded DNA antibodies, and extractable nuclear antigen antibodies.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,50</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">In their typical forms, psoriasis and SLE are easily differentiated. However, the differential diagnosis can sometimes be difficult because the clinical spectrum, mainly of SLE, is very broad.<a class="elsevierStyleCrossRefs" href="#bib0200"><span class="elsevierStyleSup">40,51</span></a> The LE lesions most often confused with psoriasis lesions are those caused by subacute lupus,<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,50–52</span></a> a disorder in which psoriasiform lesions have been reported in 15% to 50% of patients.<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">53</span></a> Cases of SLE associated not only with classic psoriasis skin lesions but also with psoriatic arthritis have recently been reported<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a>; this association has implications for differential diagnosis, treatment, and prognosis.</p><p id="par0100" class="elsevierStylePara elsevierViewall">Choice of treatment is the main problem in patients with concurrent SLE and psoriasis. UV radiation, one of the principal treatments for psoriasis, can trigger and worsen SLE.<a class="elsevierStyleCrossRefs" href="#bib0275"><span class="elsevierStyleSup">55,56</span></a> Although the outcome is favorable in most cases, toxic epidermal necrolysis has been reported in a patient treated with UV-B for psoriasis who had a history of SLE which he omitted to mention.<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">48</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Antimalarial agents (hydroxychloroquine, chloroquine) are among the drugs most often used to manage both cutaneous and systemic LE, and it is well known that these drugs can trigger or aggravate psoriasis.<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">57</span></a> In vitro studies have shown that hydroxychloroquine produces hyperproliferation and irregular keratinization in skin taken from patients with psoriasis.<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">58</span></a> However, cases have been reported in which the course of psoriasis was not altered when hydroxychloroquine was prescribed to patients with concomitant SLE.<a class="elsevierStyleCrossRefs" href="#bib0255"><span class="elsevierStyleSup">51,59</span></a> Another treatment-related problem is the risk of triggering a severe psoriasis flare when systemic corticosteroids are prescribed to manage SLE. In theory, the systemic use of corticosteroids would be contraindicated in patients with psoriasis owing to the possibility of psoriatic erythroderma.<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">57</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">Drugs that inhibit TNF-α (anti-TNF-α agents) are currently one of the main treatments for severe psoriasis.<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">60</span></a> These drugs have been somewhat effective when occasionally used to treat patients with SLE,<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">51</span></a> but there have been reports of exacerbation of SLE following their use, most often in the case of infliximab<a class="elsevierStyleCrossRefs" href="#bib0255"><span class="elsevierStyleSup">51,61</span></a> and etanercept.<a class="elsevierStyleCrossRefs" href="#bib0310"><span class="elsevierStyleSup">62,63</span></a> These reports raise the question of whether SLE is a contraindication to the use of anti-TNF agents.<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">64</span></a> Drug-induced lupus, sometimes involving anti-TNF-α agents, has also been described. However, some authors believe that TNF inhibitors give rise to a very specific clinical picture—known as anti-TNF-α-induced lupus (ATIL)—a much less common entity than drug-induced lupus and one with different characteristics.<a class="elsevierStyleCrossRefs" href="#bib0325"><span class="elsevierStyleSup">65,66</span></a> ATIL is characterized by a higher incidences of hypocomplementemia and high titers of anti-DNA antibodies in comparison with drug-induced lupus, while in the latter there will be higher titers of anti-histone antibodies. Renal and central nervous system involvement is more common in ATIL than in drug-induced lupus. ATIL is a self-limiting condition that usually disappears upon withdrawal of the anti-TNF-α therapy, but it may occasionally require treatment with corticosteroids or immunosuppressants.</p><p id="par0115" class="elsevierStylePara elsevierViewall">Methotrexate has been used successfully to treat patients with coexistent SLE and psoriasis<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">67</span></a> and is emerging as one of the best therapeutic options in this setting.<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">68</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Dermatomyositis and Psoriasis</span><p id="par0120" class="elsevierStylePara elsevierViewall">DM is an autoimmune connective tissue disease with characteristic skin involvement and muscle inflammation.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> It belongs to a group of idiopathic inflammatory myopathies that includes polymyositis and inclusion body myositis. DM is suspected based on clinical criteria, elevated serum muscle enzyme (creatine-kinase), and electromyographic abnormalities. Diagnosis is confirmed by muscle biopsy. Several diagnostic criteria have been proposed to establish whether a diagnosis of DM is probable or possible in cases in which the decision is unclear (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>).<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0125" class="elsevierStylePara elsevierViewall">Few cases of patients with coexistent DM and psoriasis have been reported. In some, DM developed in patients with a long-standing history of psoriasis.<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">69</span></a> The opposite situation can also occur, with psoriasis developing in a patient with DM.<a class="elsevierStyleCrossRef" href="#bib0350"><span class="elsevierStyleSup">70</span></a> In all published cases, the course of each disease is independent.</p><p id="par0130" class="elsevierStylePara elsevierViewall">DM sometimes presents without muscle involvement, and in such cases is called amyopathic DM.<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">71</span></a> When this occurs, cutaneous manifestations may initially be the only diagnostic criteria, making it important to stress that, in such cases, the clinical picture is often atypical and can mimic other skin diseases, such as psoriasis. One atypical manifestation of DM is scalp involvement presenting as erythema, desquamation and atrophy; in the absence of other manifestations, these symptoms may be confused with psoriasis of the scalp.<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">72</span></a> Cutaneous symptoms affecting the extensor surfaces of the hands (Gottron papules) have been reported as well as rashes that have initially been erroneously diagnosed as psoriasis.<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">73</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">Physicians should be aware of the problems involved in the treatment of patients who present with both these diseases. Although hydroxyurea is rarely prescribed in the management of psoriasis, its safety and efficacy in this setting has been demonstrated.<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">74</span></a> The side effects reported in patients receiving prolonged treatment with hydroxyurea for psoriasis include clinical signs similar to those of dermatomyositis.<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">75</span></a> Psoralen UV-A (PUVA) treatment, unlike hydroxyurea, is frequently used to manage psoriasis, and a case in which DM developed during such treatment has been reported.<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">76</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">In patients with DM, prognosis is determined by the systemic manifestations, which primarily affect the muscles, lungs, and heart. Muscle damage and interstitial lung disease require treatment with high doses of oral corticosteroids. Since these drugs are contraindicated in patients with psoriasis, other immunomodulatory and immunosuppressive therapies, such as methotrexate or azathioprine may be prescribed.<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">57</span></a> Tacrolimus and mycophenolate mofetil have also been shown to be useful in interstitial lung disease.<a class="elsevierStyleCrossRefs" href="#bib0385"><span class="elsevierStyleSup">77,78</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">Instances have been reported of improvement in both skin and muscle symptoms in patients with DM or polymyositis treated with anti-TNF-α following poor response to other classic treatments, such as methotrexate.<a class="elsevierStyleCrossRef" href="#bib0395"><span class="elsevierStyleSup">79</span></a> Such an outcome would be of great interest in a patient with concomitant psoriasis.Finally, we note that ciclosporin A, a drug widely used in patients with psoriasis, has been used successfully to treat cases of refractory DM and polymyositis.<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">80</span></a> Because ciclosporin can cause myolysis, some authors recommend that this drug be prescribed on a case by case basis in these patients.<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">81–83</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Scleroderma and Psoriasis</span><p id="par0150" class="elsevierStylePara elsevierViewall">Systemic scleroderma is a multisystem autoimmune connective tissue disease of unknown etiology<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,37</span></a> characterized by generalized vascular involvement that results in tissue ischemia and secondary fibrosis. There are 2 main types: limited and diffuse. As in other rheumatic diseases, diagnosis is based on clinical criteria (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>). While skin involvement is the main clinical feature, prognosis depends on the systemic manifestations.</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0155" class="elsevierStylePara elsevierViewall">Very few cases of concomitant psoriasis and systemic sclerosis have been reported,<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">84–88</span></a> with the largest series in the literature involving only 3 cases.<a class="elsevierStyleCrossRefs" href="#bib0435"><span class="elsevierStyleSup">87,88</span></a> Of particular interest is the study by Harrison et al,<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">88</span></a> in which the prevalence of psoriasis in patients with systemic scleroderma was 5.3%. Some authors have suggested that the 2 entities may share a common genetic and immunologic basis,<a class="elsevierStyleCrossRefs" href="#bib0435"><span class="elsevierStyleSup">87,88</span></a> and although the HLA DRw52 serotype has been associated with both systemic scleroderma and psoriasis, studies have failed to establish an HLA pattern in patients with both diseases. It has also been suggested that the skin alterations caused by psoriasis may act as a triggering factor for systemic sclerosis because in some patients the development of psoriasis was followed by the onset of scleroderma.<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">88</span></a></p><p id="par0160" class="elsevierStylePara elsevierViewall">Most reported cases deal with patients who had a long history of psoriasis prior to the onset of scleroderma. The most common type of scleroderma developed is the diffuse systemic form. Several authors indicate that the symptoms of systemic sclerosis may be more aggressive in these patients in comparison to the moderate severity of their psoriasis.<a class="elsevierStyleCrossRefs" href="#bib0435"><span class="elsevierStyleSup">87,88</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">The typical clinical features of systemic scleroderma are not usually confused with psoriasis, and although scleroderma is rarely accompanied by joint involvement, this symptom has been reported in a few cases.<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">89,90</span></a> Occasionally, joint involvement in a patient with scleroderma may be confused with or mask psoriatic arthritis with minimal skin involvement.<a class="elsevierStyleCrossRef" href="#bib0455"><span class="elsevierStyleSup">91</span></a></p><p id="par0170" class="elsevierStylePara elsevierViewall">Several issues must be taken into account in the treatment of patients with these 2 diseases. Raynaud phenomenon, a disorder characterized by vasospasm of the small distal vasculature (usually in response to cold) and manifested as pallor, cyanosis and hyperemia, is one of the most common presentations of systemic scleroderma.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> This condition is treated with a variety of drugs, the most common of which are calcium channel blockers, such as nifedipine, although losartan (an angiotensin II receptor antagonist) has also been used successfully. Both of these drugs reduce the severity of symptoms, but only losartan reduces the frequency of episodes.<a class="elsevierStyleCrossRef" href="#bib0460"><span class="elsevierStyleSup">92</span></a> Although no strong association between psoriasis and calcium channel blockers has been established, cases in which psoriasis developed following the use of these drugs have been reported.<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">93,94</span></a> The onset of psoriasis has also been associated with angiotensin II inhibitors; in most published cases, the psoriasis symptoms resolved over the following months.<a class="elsevierStyleCrossRefs" href="#bib0475"><span class="elsevierStyleSup">95,96</span></a> The endothelin receptor antagonist bosentan has proven effective in preventing ulcers caused by Raynaud phenomenon, but has not been shown to aid the resolution of existing lesions.<a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">97</span></a> We have found no evidence in the literature linking treatment with bosentan to the development of psoriasis.</p><p id="par0175" class="elsevierStylePara elsevierViewall">The systemic manifestations of scleroderma include kidney damage that can result in renal crisis, the leading cause of death in this setting until the introduction of angiotensin-converting enzyme inhibitors.<a class="elsevierStyleCrossRefs" href="#bib0185"><span class="elsevierStyleSup">37,98</span></a> These drugs have been clearly implicated in triggering outbreaks of psoriasis.<a class="elsevierStyleCrossRefs" href="#bib0470"><span class="elsevierStyleSup">94,95,99,100</span></a> However, due to the seriousness of the renal complications of scleroderma, these drugs should be used even at the risk of exacerbating psoriasis.</p><p id="par0180" class="elsevierStylePara elsevierViewall">Pulmonary hypertension is currently the leading cause of death in these patients. Several treatment options are available, including cyclophosphamide, bosentan, sildenafil, prostacyclin derivatives and oral corticosteroids. We have found no evidence in the literature suggesting that these drugs, with the exception of oral corticosteroids, either induce or exacerbate psoriasis. Moreover, cases have been reported in which no exacerbation of psoriasis was observed following treatment with corticosteroids in patients with systemic scleroderma.<a class="elsevierStyleCrossRef" href="#bib0435"><span class="elsevierStyleSup">87</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Rheumatoid Arthritis and Psoriasis</span><p id="par0185" class="elsevierStylePara elsevierViewall">RA is an autoimmune disease of unknown etiology characterized by chronic and debilitating symmetrical polyarthritis accompanied by systemic manifestations that can occasionally be life threatening. Its exact etiology is unknown. Like the other diseases discussed above, RA is diagnosed on the basis of clinical criteria (<a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a>).</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><p id="par0190" class="elsevierStylePara elsevierViewall">Although neither RA nor psoriasis is uncommon, they rarely occur concomitantly. In 1992, Mazzucchelli et al<a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">101</span></a> estimated the prevalence of this association to be between 0.03 and 0.15 per 10 000 population. More recent data from a German database of rheumatic diseases indicate that 0.2% of patients with RA and 0.3% of RA seropositive patients have concomitant psoriasis.<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">102</span></a></p><p id="par0195" class="elsevierStylePara elsevierViewall">The extra-articular manifestations of RA include associated dermatologic manifestations, such as rheumatoid nodules (a diagnostic criterion), rheumatoid vasculitis, pyoderma gangrenosum, and rheumatoid neutrophilic dermatosis.<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">57</span></a> Cases of palmoplantar pustulosis associated with neutrophilic dermatosis have also been reported.<a class="elsevierStyleCrossRef" href="#bib0515"><span class="elsevierStyleSup">103</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">Although the diagnosis of these entities is not difficult when they occur separately, problems do arise when inflammatory arthritis develops in a patient who has psoriasis. The clinical picture in such cases is usually suggestive of psoriatic arthritis, but we must nonetheless also consider the possibility of other types of inflammatory arthritis, such as RA.</p><p id="par0205" class="elsevierStylePara elsevierViewall">Psoriatic arthritis presents as oligoarthritis, which is usually asymmetrical, primarily affects the distal interphalangeal joints, and is often associated with spondyloarthropathy, dactylitis and nail dystrophy. Juxtaarticular new bone formation is a characteristic radiographic finding. By contrast, RA primarily affects metacarpophalangeal and proximal interphalangeal joints, making it possible in most cases to distinguish the disease on the basis of clinical findings.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> The radiograph demonstrates bone erosion and decalcification in the regions adjacent to clinically affected joints.</p><p id="par0210" class="elsevierStylePara elsevierViewall">Nonetheless, it is sometimes difficult to differentiate between the 2 diseases, particularly when psoriatic arthritis has a polyarticular pattern.<a class="elsevierStyleCrossRef" href="#bib0520"><span class="elsevierStyleSup">104</span></a> Certain serologic markers, such as rheumatoid factor and the anticyclic citrullinated peptide antibody, can help to establish a diagnosis; these findings must, however, be interpreted with caution. Rheumatoid factor is found in 85% of patients with RA and is considered a diagnostic criterion. Nevertheless, it is also found in conjunction with other diseases and in healthy populations.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> Rheumatoid factor has traditionally been considered indicative of RA, but this antibody has also been found in between 2% and 10% of patients with psoriatic arthritis.<a class="elsevierStyleCrossRef" href="#bib0520"><span class="elsevierStyleSup">104</span></a> As noted above, another serologic marker used is the anticyclic citrullinated peptide antibody, which is highly specific for RA<a class="elsevierStyleCrossRef" href="#bib0525"><span class="elsevierStyleSup">105</span></a> and has been used to distinguish RA from other diseases. However, this antibody is also found in 8% to 16% of patients with psoriatic arthritis (more frequently in those with erosive polyarticular disease), and it may even be found in psoriasis patients who have no joint involvement.<a class="elsevierStyleCrossRef" href="#bib0530"><span class="elsevierStyleSup">106</span></a> Thus, the presence of anticyclic citrullinated peptide antibody or rheumatoid factor does not exclude a diagnosis of psoriatic arthritis.</p><p id="par0215" class="elsevierStylePara elsevierViewall">As noted above, the diagnosis of psoriatic arthritis is difficult because it is based on clinical, radiographic, and immunologic findings; there are no internationally accepted criteria.<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">107</span></a> Taylor et al<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">108</span></a> recently suggested a set of criteria called CASPAR (Classification of Psoriatic Arthritis), which has a sensitivity of 91.4% and a specificity 98.7% in this disease. Under the CASPAR criteria, the diagnosis of psoriatic arthritis requires at least 3 points according to the following scoring system: current psoriasis (2 points) or history of psoriasis (1 point), family history of psoriasis (1 point unless current psoriasis is present or there was a history of psoriasis), dactylitis (1 point), juxtaarticular new bone formation (1 point), rheumatoid factor negativity (1 point), and nail dystrophy (1 point).</p><p id="par0220" class="elsevierStylePara elsevierViewall">The introduction of biologic drugs has brought an important change in the management of RA. Anti-TNF-α agents (etanercept, infliximab and adalimumab) are now widely prescribed for these patients and the same drugs are also used to treat patients with severe psoriasis or psoriatic arthritis. However, paradoxically, these agents have been known to trigger an outbreak of psoriasis or psoriasiform dermatitis.<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">109</span></a> The incidence of psoriasis induced by TNF-α-blocking therapy in patients with RA is estimated to be between 2.3% and 5%.<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">110</span></a></p><p id="par0225" class="elsevierStylePara elsevierViewall">In short, the diagnosis of coexistent psoriasis and RA represents a real challenge for both the dermatologist and the rheumatologist, and the association has both therapeutic and prognostic implications.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conclusions</span><p id="par0230" class="elsevierStylePara elsevierViewall">In conclusion we note that, despite the fact that psoriasis is a relatively common disease in the general population, its simultaneous occurrence with connective tissue or rheumatic diseases is quite rare. However, the implications of such associations are important. In recent years, we have gained a better understanding of the etiology and pathogenesis of both psoriasis and the connective tissue diseases, an advance that has facilitated the detection of the common pathogenic pathways that shape the clinical characteristics of these associations and inform the appropriate therapeutic approach for each case. Because of the particular clinical characteristics of these associations and, more especially, the therapeutic approaches required in this setting, individual assessment of each patient is essential and this will often require collaboration between the rheumatologist and the dermatologist.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conflicts of Interest</span><p id="par0235" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:13 [ 0 => array:2 [ "identificador" => "xres95346" "titulo" => "Abstract" ] 1 => array:2 [ "identificador" => "xpalclavsec82505" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres95345" "titulo" => "Resumen" ] 3 => array:2 [ "identificador" => "xpalclavsec82506" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Immunopathogenesis of Psoriasis and Autoimmune Connective Tissue Diseases" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Systemic Lupus Erythematosus and Psoriasis" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Dermatomyositis and Psoriasis" ] 8 => array:2 [ "identificador" => "sec0025" "titulo" => "Scleroderma and Psoriasis" ] 9 => array:2 [ "identificador" => "sec0030" "titulo" => "Rheumatoid Arthritis and Psoriasis" ] 10 => array:2 [ "identificador" => "sec0035" "titulo" => "Conclusions" ] 11 => array:2 [ "identificador" => "sec0040" "titulo" => "Conflicts of Interest" ] 12 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2010-12-11" "fechaAceptado" => "2011-03-02" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec82505" "palabras" => array:5 [ 0 => "Psoriasis" 1 => "Dermatomyositis" 2 => "Rheumatoid arthritis" 3 => "Systemic lupus erythematosus" 4 => "Scleroderma" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec82506" "palabras" => array:5 [ 0 => "Psoriasis" 1 => "Dermatomiositis" 2 => "Artritis reumatoide" 3 => "Lupus eritematoso sistémico" 4 => "Esclerodermia" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Psoriasis is an autoimmune chronic inflammatory skin disease that is common in Spain. Connective tissue diseases are a heterogeneous group of conditions characterized by the abnormal function or structure of one or more of the elements that make up connective tissue. These diseases are also autoimmune in origin. In spite of the high prevalence of psoriasis in the general population, its association with a connective tissue disease such as systemic lupus erythematosus, dermatomyositis, scleroderma, or rheumatoid arthritis has only occasionally been reported. It is nevertheless important to have an understanding of such associations, given their significant clinical and therapeutic implications. The association between psoriasis and systemic lupus erythematosus is the one most often described, although the few reports available in the literature have mostly involved single cases. This review will also look at the characteristics of patients with psoriasis and dermatomyositis, mainly focusing on clinical features. The associations between psoriasis and either rheumatoid arthritis or systemic sclerosis will be examined more briefly. The review therefore aims to reflect the literature on psoriasis in association with rheumatic diseases, including coverage of etiologic, pathogenic, clinical, and therapeutic aspects. We emphasize that such cases should be managed by a multidisciplinary team in which care will usually be shared by a rheumatologist and a dermatologist.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La psoriasis es una enfermedad cutánea inflamatoria crónica de etiología autoinmune muy frecuente en nuestro medio. Las enfermedades del tejido conectivo constituyen un grupo heterogéneo de enfermedades que se caracterizan por la anormal función o estructura de uno o varios elementos del tejido conectivo, de origen autoinmune. Pese a la alta frecuencia de la psoriasis en la población general, son pocos los casos publicados en los que coexistan psoriasis y enfermedades del tejido conectivo, como lupus eritematoso sistémico, dermatomiositis, esclerodermia o artritis reumatoide. Sin embargo, dadas las implicaciones clínicas y, principalmente, terapéuticas que presentan estos pacientes, resulta importante conocer estas asociaciones. La más frecuentemente descrita es la de psoriasis y lupus eritematoso sistémico, aunque son pocos los estudios publicados y la mayoría se basan en casos únicos. También trataremos las características específicas de los pacientes con dermatomiositis y psoriasis, principalmente de tipo clínico. Abordaremos de forma más breve la coexistencia de esclerosis sistémica y psoriasis, y de artritis reumatoide y psoriasis. Se pretende, por tanto, realizar una revisión de la literatura sobre psoriasis y su coexistencia con enfermedades reumatológicas, que comprende aspectos etiopatogénicos, clínicos y terapéuticos. Además queremos resaltar el manejo multidisciplinar que requieren estos pacientes, generalmente entre el reumatólogo y el dermatólogo.</p>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara">Please cite this article as: Cuesta-Montero L, Belinchón I. Conectivopatías y psoriasis. Actas Dermosifiliogr. 2011;102:487-97.</p>" ] ] "multimedia" => array:6 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1736 "Ancho" => 2403 "Tamanyo" => 196687 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Naive T helper (T<span class="elsevierStyleInf">H</span>) cells differentiate into 3 different subsets (T<span class="elsevierStyleInf">H</span>1,T<span class="elsevierStyleInf">H</span>2,and T<span class="elsevierStyleInf">H</span>17) depending on the cytokine stimuli they receive. Transforming growth factor (TGF) β and interleukin (IL) 6 are the primary mediators of differentiation into T<span class="elsevierStyleInf">H</span>17 cells, while IL-23 contributes to the survival and proliferation of these cells. Among the many cytokines secreted by T<span class="elsevierStyleInf">H</span>17 cells, IL-21 intervenes in a positive feedback loop. IFN indicates interferon; TNF, tumor necrosis factor.</p>" ] ] 1 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diffuse connective tissue diseases \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Arthritis associated with spondylitis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Osteoarthritis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rheumatic syndromes associated with infectious agents \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Metabolic and endocrine diseases associated with rheumatic states \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Neoplasms \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Neurovascular disorders \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Bone and cartilage disorders \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Joint disorders \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Miscellaneous disorders associated with articular manifestations \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab181788.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">The American College of Rheumatology 1983 Classification of Rheumatic Diseases (Adapted).<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p>" ] ] 2 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Malar rash \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Discoid rash \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Photosensitivity \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral ulcers \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Arthritis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Serositis: pleuritis or pericarditis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Renal disorder: proteinuria (<0.5 g/d) or cellular casts \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Neurologic disorder: seizures or psychosis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hematologic disorder: hemolytic anemia, leukopenia, lymphocytopenia or thrombocytopenia \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Immunologic disorder: anti-DNA, anti-smooth muscle, or antiphospholipid antibodies \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Antinuclear antibodies \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab181790.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara">A case must fulfill at least 4 criteria for the diagnosis of systemic lupus erythematosus to be confirmed.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">The 1982 Revised Criteria<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> of the American College of Rheumatology for the Classification of Systemic Lupus Erythematosus.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p>" ] ] 3 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">A history of symmetrical weakness of the girdle muscles and/or cervical flexors lasting weeks or months</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Histology: necrosis of type I and II muscle fibers, phagocytosis, perifascicular atrophy, and regeneration</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Elevation of serum skeletal muscle enzymes</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Electromyographic evidence of myopathic motor units, fibrillation, positive waves and insertional irritability</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Heliotrope rash, erythematous rash on the face, chest, extensor surfaces of limbs and Gottron papules</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Polymyositis</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Definite: 4 criteria \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Probable: 3 criteria \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Possible: 2 criteria \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Dermatomyositis (the fifth criterion must always be present)</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Definite: 3 of the other 4 criteria \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Probable: 2 of the other 4 criteria \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Possible: 1 of the other 4 criteria \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab181791.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Criteria for the Diagnosis of Dermatomyositis-Polymyositis.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p>" ] ] 4 => array:7 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Major Findings</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Sclerosis proximal to the metacarpophalangeal joints of the hands or the metatarsophalangeal joints of the feet \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Minor Findings</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Sclerodactyly \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Digital pitting scars or loss of substance of the finger pad \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Bilateral basilar pulmonary fibrosis \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab181789.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara">One major finding or 2 minor findings must be present to confirm the diagnosis of scleroderma.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">The American College of Rheumatology 1980 Diagnostic Criteria for Systemic Sclerosis.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p>" ] ] 5 => array:7 [ "identificador" => "tbl0025" "etiqueta" => "Table 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Morning stiffness \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Morning stiffness in and around joints lasting for at least one hour \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Arthritis in 3 or more joint areas \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Involvement of at least 3 joint areas simultaneously with soft tissue swelling or accumulation of joint fluid observed by a physician. The possible areas involved are the left and right proximal interphalangeal, metacarpophalangeal, wrist, elbow, knee, and metatarsophalangeal joints. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Arthritis of hand joints \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Affecting at least 1 area in the wrist, metacarpophalangeal or proximal interphalangeal joint \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Symmetrical arthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Simultaneous involvement of the same joint areas on both sides of the body \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rheumatoid nodules \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Subcutaneous nodules over bony prominences, extensor surfaces, or juxtaarticular regions observed by a physician \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Positive serum rheumatoid factor \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Radiographic changes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Erosions or unequivocal bone decalcification localized in the regions adjacent to the involved joints is \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab181787.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara">Source: Adapted from Wolf K, et al<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a><span class="elsevierStyleSup">.</span></p>" ] 1 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara">Four of the 7 findings must be present to confirm the diagnosis of rheumatoid arthritis. The first 4 criteria must have been present for at least 6 weeks.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Revised Criteria Proposed by the American College of Rheumatology for the Classification of Rheumatoid Arthritis, 1987<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a><span class="elsevierStyleSup">,</span>.<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">b</span></a></p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:110 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Manual SER de las enfermedades reumáticas" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:4 [ "edicion" => "4.<span class="elsevierStyleSup">a</span> ed." "fecha" => "2004" "editorial" => "Médica Panamericana" "editorialLocalizacion" => "Madrid" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of psoriasis in Spain (Epiderma Project: Phase I)" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2001" "volumen" => "15" "paginaInicial" => "20" "paginaFinal" => "23" "link" => array:1 [ …1] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Coexistence of five autoimmune diseases: diagnostic and therapeutic difficulties" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-008-0544-5" "Revista" => array:6 [ "tituloSerie" => "Rheumatol Int" "fecha" => "2008" "volumen" => "28" "paginaInicial" => "919" "paginaFinal" => "923" "link" => array:1 [ …1] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Coexistence of subacute cutaneous lupus erythematosus and psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2004.00916.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2004" "volumen" => "18" "paginaInicial" => "390" "paginaFinal" => "391" "link" => array:1 [ …1] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estudio EPISER: Prevalencia de las enfermedades reumáticas en la población española" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2001" "editorial" => "Merck, Sharp & Dohme" "editorialLocalizacion" => "España" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Lupus" "fecha" => "2003" "volumen" => "12" "paginaInicial" => "860" "paginaFinal" => "865" "link" => array:1 [ …1] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Polymyositis-Dermatomyositis: incidence in Spain (1997-2004)" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Med Clin (Barc)" "fecha" => "2007" "volumen" => "129" "paginaInicial" => "721" "paginaFinal" => "724" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of scleroderma in Spain: an approach for estimating rare disease prevalence using a disease model" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/pds.1660" "Revista" => array:6 [ "tituloSerie" => "Pharmacoepidemiol Drug Saf" "fecha" => "2008" "volumen" => "17" "paginaInicial" => "1100" "paginaFinal" => "1107" "link" => array:1 [ …1] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etiopatogenia, clínica y diagnóstico" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:4 [ "titulo" => "Manual de Dermatología" "paginaInicial" => "171" "paginaFinal" => "184" "serieFecha" => "2010" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Fitzpatrick. Dermatología en Medicina General" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:4 [ "edicion" => "7th ed." "fecha" => "2009" "editorial" => "Editorial Médica Panamericana" "editorialLocalizacion" => "Madrid" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "N Engl J Med" "fecha" => "2009" "volumen" => "36" "paginaInicial" => "496" "paginaFinal" => "509" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The natural history of psoriasis in 5,600 patients" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Dermatologica" "fecha" => "1974" "volumen" => "148" "paginaInicial" => "1" "paginaFinal" => "18" "link" => array:1 [ …1] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Getting under the skin: the immunogenetics of psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nri1689" "Revista" => array:6 [ "tituloSerie" => "Nat Rev Immunol" "fecha" => "2005" "volumen" => "5" "paginaInicial" => "699" "paginaFinal" => "711" "link" => array:1 [ …1] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Hum Mol Genet" "fecha" => "1997" "volumen" => "6" "paginaInicial" => "813" "paginaFinal" => "820" "link" => array:1 [ …1] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.0022-202X.2004.23511.x" "Revista" => array:6 [ "tituloSerie" => "J Invest Dermatol" "fecha" => "2005" "volumen" => "124" "paginaInicial" => "103" "paginaFinal" => "106" "link" => array:1 [ …1] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1046/j.1523-1747.2003.12094.x" "Revista" => array:6 [ "tituloSerie" => "J Invest Dermatol" "fecha" => "2003" "volumen" => "120" "paginaInicial" => "627" "paginaFinal" => "632" "link" => array:1 [ …1] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/511051" "Revista" => array:6 [ "tituloSerie" => "Am J Hum Genet" "fecha" => "2007" "volumen" => "80" "paginaInicial" => "273" "paginaFinal" => "290" "link" => array:1 [ …1] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/jmg.2007.053595" "Revista" => array:6 [ "tituloSerie" => "J Med Genet" "fecha" => "2008" "volumen" => "45" "paginaInicial" => "114" "paginaFinal" => "116" "link" => array:1 [ …1] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/jid.2008.297" "Revista" => array:6 [ "tituloSerie" => "J Invest Dermatol" "fecha" => "2009" "volumen" => "129" "paginaInicial" => "629" "paginaFinal" => "634" "link" => array:1 [ …1] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Th 17 cells in rheumatoid arthritis and systemic lupus erythematosus" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2796.2009.02099.x" "Revista" => array:6 [ "tituloSerie" => "J Intern Med" "fecha" => "2009" "volumen" => "265" "paginaInicial" => "644" "paginaFinal" => "652" "link" => array:1 [ …1] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Th17 cells in human disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1600-065X.2008.00628.x" "Revista" => array:6 [ "tituloSerie" => "Immunol Rev" "fecha" => "2008" "volumen" => "223" "paginaInicial" => "87" "paginaFinal" => "113" "link" => array:1 [ …1] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of T helper 17 (Th17) and regulatory cells (Treg) in human organ transplantation and autoimmune disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2249.2007.03356.x" "Revista" => array:6 [ "tituloSerie" => "Clin Exp Immunol" "fecha" => "2007" "volumen" => "148" "paginaInicial" => "32" "paginaFinal" => "46" "link" => array:1 [ …1] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IL-21 in the pathogenesis and treatment of skin diseases" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jdermsci.2010.08.016" "Revista" => array:6 [ "tituloSerie" => "J Dermatol Sci" "fecha" => "2010" "volumen" => "60" "paginaInicial" => "61" "paginaFinal" => "66" "link" => array:1 [ …1] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Curr Rheumatol Rep" "fecha" => "2007" "volumen" => "9" "paginaInicial" => "461" "paginaFinal" => "467" "link" => array:1 [ …1] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nm.1995" "Revista" => array:6 [ "tituloSerie" => "Nat Med" "fecha" => "2009" "volumen" => "15" "paginaInicial" => "1013" "paginaFinal" => "1015" "link" => array:1 [ …1] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.it.2008.02.008" "Revista" => array:6 [ "tituloSerie" => "Trends Immunol" "fecha" => "2008" "volumen" => "29" "paginaInicial" => "290" "paginaFinal" => "294" "link" => array:1 [ …1] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IL-17 and the Th17 lineage in systemic lupus erythematosus" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/BOR.0b013e328304b6b5" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Rheumatol" "fecha" => "2008" "volumen" => "20" "paginaInicial" => "519" "paginaFinal" => "525" "link" => array:1 [ …1] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Gut" "fecha" => "2009" "volumen" => "58" "paginaInicial" => "799" "paginaFinal" => "804" "link" => array:1 [ …1] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genome-wide association scan in psoriasis: new insights into chronic inflammatory disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/1744666X.4.5.565" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Clin Immunol" "fecha" => "2008" "volumen" => "4" "paginaInicial" => "565" "paginaFinal" => "571" "link" => array:1 [ …1] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.humimm.2007.01.009" "Revista" => array:6 [ "tituloSerie" => "Hum Immunol" "fecha" => "2007" "volumen" => "68" "paginaInicial" => "384" "paginaFinal" => "391" "link" => array:1 [ …1] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Testing for the association of the KIAA1109/Tenr/IL2/IL21 gene region with rheumatoid arthritis in a European family-based study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/ar2654" "Revista" => array:5 [ "tituloSerie" => "Arthritis Res Ther" "fecha" => "2009" "volumen" => "11" "paginaInicial" => "R45" "link" => array:1 [ …1] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A common exonic variant of interleukin 21 confers susceptibility to atopic asthma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000155744" "Revista" => array:6 [ "tituloSerie" => "Int Arch Allergy Immunol" "fecha" => "2009" "volumen" => "148" "paginaInicial" => "137" "paginaFinal" => "146" "link" => array:1 [ …1] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two year prospective study (the DAMAGE study cohort)" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.21749" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2006" "volumen" => "54" "paginaInicial" => "1122" "paginaFinal" => "1131" "link" => array:1 [ …1] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IL-21 regulates Th17 cells in rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.humimm.2010.01.010" "Revista" => array:6 [ "tituloSerie" => "Hum Immunol" "fecha" => "2010" "volumen" => "71" "paginaInicial" => "334" "paginaFinal" => "341" "link" => array:1 [ …1] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.22452" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2007" "volumen" => "56" "paginaInicial" => "1152" "paginaFinal" => "1163" "link" => array:1 [ …1] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interferon-alpha controls IL-17 expression <span class="elsevierStyleItalic">in vitro</span> and <span class="elsevierStyleItalic">in vivo</span>" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.imbio.2008.07.022" "Revista" => array:6 [ "tituloSerie" => "Immunobiology" "fecha" => "2008" "volumen" => "213" "paginaInicial" => "779" "paginaFinal" => "787" "link" => array:1 [ …1] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Update on connective tissue diseases in dermatology" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.sder.2006.08.004" "Revista" => array:6 [ "tituloSerie" => "Semin Cutan Med Surg" "fecha" => "2006" "volumen" => "25" "paginaInicial" => "207" "paginaFinal" => "220" "link" => array:1 [ …1] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The coexistence of systemic lupus erythematosus with other autoimmune diseases: the kaleidoscope of autoimmunity" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "1994" "volumen" => "24" "paginaInicial" => "105" "paginaFinal" => "113" "link" => array:1 [ …1] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Linear psoriasis associated with systemic lupus" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1994" "volumen" => "30" "paginaInicial" => "130" "paginaFinal" => "133" "link" => array:1 [ …1] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0200" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Coexistent psoriasis and lupus erythematosus: what's happening?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Cutis" "fecha" => "1985" "volumen" => "36" "paginaInicial" => "449" "paginaFinal" => "450" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0205" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Superantigens in human disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Sci Am" "fecha" => "1992" "volumen" => "266" "paginaInicial" => "42" "paginaFinal" => "48" "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0210" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chronic lupus disseminatus and psoriasis vulgaris" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Arch Dermatol Syphilol" "fecha" => "1936" "volumen" => "15" "paginaInicial" => "92" ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0215" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The coexistence of psoriasis and lupus erythematosus. An analysis of 27 cases" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "1980" "volumen" => "116" "paginaInicial" => "658" "paginaFinal" => "663" "link" => array:1 [ …1] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0220" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lupus erythematosus and psoriasis vulgaris" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cutis" "fecha" => "1978" "volumen" => "21" "paginaInicial" => "511" "paginaFinal" => "525" "link" => array:1 [ …1] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0225" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Annular pustular psoriasis and systemic lupus erythematosus" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol" "fecha" => "1990" "volumen" => "29" "paginaInicial" => "290" "paginaFinal" => "292" "link" => array:1 [ …1] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0230" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Acta Derm Venereol" "fecha" => "1996" "volumen" => "195" "numero" => "Suppl" "paginaInicial" => "1" "paginaFinal" => "15" ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0235" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lupus erythematosus" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:4 [ "edicion" => "7th ed." "fecha" => "2006" "editorial" => "Lippincott Williams and Wilkings" "editorialLocalizacion" => "Filadelfia" ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0240" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serologic studies in patients with lupus erythematosus and psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1983" "volumen" => "8" "paginaInicial" => "631" "paginaFinal" => "634" "link" => array:1 [ …1] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0245" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The coexistence of systemic lupus erythematosus and psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1984" "volumen" => "10" "paginaInicial" => "619" "paginaFinal" => "622" "link" => array:1 [ …1] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0250" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis coexisting with subacute cutaneous lupus erythematosus" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2004.00817.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2004" "volumen" => "18" "paginaInicial" => "385" "paginaFinal" => "386" "link" => array:1 [ …1] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0255" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Collagen vascular diseases" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2004.04.007" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2004" "volumen" => "51" "paginaInicial" => "427" "paginaFinal" => "439" "link" => array:1 [ …1] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0260" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Coexistent psoriasis and lupus erythematosus treated with alefacept" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Clin Dermatol" "fecha" => "2007" "volumen" => "8" "paginaInicial" => "47" "paginaFinal" => "50" "link" => array:1 [ …1] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0265" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus. Diagnostic criteria and therapeutic implications" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1998" "volumen" => "38" "paginaInicial" => "405" "paginaFinal" => "412" "link" => array:1 [ …1] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0270" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Coexistence of psoriatic arthritis and systemic lupus erythematosus" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Isr Med Assoc J" "fecha" => "2007" "volumen" => "9" "paginaInicial" => "48" "paginaFinal" => "49" "link" => array:1 [ …1] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0275" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Subacute cutaneous lupus erythematosus during PUVA therapy for psoriasis; case report and review of the literature" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "1989" "volumen" => "32" "paginaInicial" => "343" "paginaFinal" => "346" "link" => array:1 [ …1] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0280" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Med Interne (Paris)" "fecha" => "2003" "volumen" => "154" "paginaInicial" => "3" "paginaFinal" => "6" ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0285" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:5 [ "titulo" => "Dermatology" "paginaInicial" => "115" "paginaFinal" => "135" "edicion" => "2nd ed." "serieFecha" => "2008" ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0290" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The in vitro effect of hydroxychloroquine on skin morphology in psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol" "fecha" => "1999" "volumen" => "38" "paginaInicial" => "154" "paginaFinal" => "157" "link" => array:1 [ …1] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0295" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hydroxychloroquine in psoriasis: is it really harmful?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2340/00015555-0141" "Revista" => array:6 [ "tituloSerie" => "Acta Derm Venereol" "fecha" => "2006" "volumen" => "86" "paginaInicial" => "450" "paginaFinal" => "451" "link" => array:1 [ …1] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0300" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2009" "volumen" => "100" "paginaInicial" => "277" "paginaFinal" => "286" "link" => array:1 [ …1] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0305" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Ther" "fecha" => "2003" "volumen" => "25" "paginaInicial" => "2487" "paginaFinal" => "2505" "link" => array:1 [ …1] ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0310" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept-induced systemic lupus erythematosus" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Exp Dermatol" "fecha" => "2003" "volumen" => "28" "paginaInicial" => "604" "paginaFinal" => "607" "link" => array:1 [ …1] ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0315" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Korean Med Sci" "fecha" => "2006" "volumen" => "21" "paginaInicial" => "649" "paginaFinal" => "946" ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0320" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Worsening of subacute lupus erythematosus induced by infliximab" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Dermatol Venereol" "fecha" => "2005" "volumen" => "132" "paginaInicial" => "349" "paginaFinal" => "353" "link" => array:1 [ …1] ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0325" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-TNF-induced lupus" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/kep080" "Revista" => array:6 [ "tituloSerie" => "Rheumatology" "fecha" => "2009" "volumen" => "48" "paginaInicial" => "716" "paginaFinal" => "720" "link" => array:1 [ …1] ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0330" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Arthritis Res Ther" "fecha" => "2005" "volumen" => "2" "paginaInicial" => "R545" "paginaFinal" => "R551" ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0335" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous lupus erythematosus: issues in diagnosis and treatment" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2165/11310780-000000000-00000" "Revista" => array:6 [ "tituloSerie" => "Am J Clin Dermatol" "fecha" => "2009" "volumen" => "10" "paginaInicial" => "365" "paginaFinal" => "381" "link" => array:1 [ …1] ] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0340" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2009.03.027" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2009" "volumen" => "61" "paginaInicial" => "451" "paginaFinal" => "485" "link" => array:1 [ …1] ] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib0345" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A man with erythrodermia, muscle weakness and weight loss" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4045/tidsskr.09.0184" "Revista" => array:6 [ "tituloSerie" => "Tidsskr Nor Laegeforen" "fecha" => "2009" "volumen" => "129" "paginaInicial" => "2240" "paginaFinal" => "2241" "link" => array:1 [ …1] ] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib0350" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis in a patient with dermatomyositis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Vojnosanit Pregl" "fecha" => "2004" "volumen" => "61" "paginaInicial" => "557" "paginaFinal" => "559" "link" => array:1 [ …1] ] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib0355" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2005.10.041" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2006" "volumen" => "54" "paginaInicial" => "597" "paginaFinal" => "613" "link" => array:1 [ …1] ] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib0360" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "JAMA" "fecha" => "1994" "volumen" => "28" "paginaInicial" => "1939" "paginaFinal" => "1941" ] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib0365" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Gottrons's papule in amyopathic dermatomyositis mimicking psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10067-009-1244-6" "Revista" => array:6 [ "tituloSerie" => "Clin Rheumatol" "fecha" => "2009" "volumen" => "28" "paginaInicial" => "1245" "paginaFinal" => "1246" "link" => array:1 [ …1] ] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib0370" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hydroxyurea in the management of therapy resistant psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "1989" "volumen" => "121" "paginaInicial" => "647" "paginaFinal" => "653" "link" => array:1 [ …1] ] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib0375" "etiqueta" => "75" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Exp Dermatol" "fecha" => "1998" "volumen" => "24" "paginaInicial" => "164" "paginaFinal" => "166" "link" => array:1 [ …1] ] ] ] ] ] ] 75 => array:3 [ "identificador" => "bib0380" "etiqueta" => "76" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dermatomyositis occurring during psoralen A (PUVA)" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "1994" "volumen" => "21" "paginaInicial" => "353" "paginaFinal" => "356" "link" => array:1 [ …1] ] ] ] ] ] ] 76 => array:3 [ "identificador" => "bib0385" "etiqueta" => "77" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Exp Rheumatol" "fecha" => "2005" "volumen" => "23" "paginaInicial" => "707" "paginaFinal" => "710" "link" => array:1 [ …1] ] ] ] ] ] ] 77 => array:3 [ "identificador" => "bib0390" "etiqueta" => "78" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.142.1.65" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2006" "volumen" => "142" "paginaInicial" => "65" "paginaFinal" => "69" "link" => array:1 [ …1] ] ] ] ] ] ] 78 => array:3 [ "identificador" => "bib0395" "etiqueta" => "79" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor alpha: preliminary observations" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "70852" "Revista" => array:6 [ "tituloSerie" => "Eur Neurol" "fecha" => "2003" "volumen" => "50" "paginaInicial" => "10" "paginaFinal" => "15" "link" => array:1 [ …1] ] ] ] ] ] ] 79 => array:3 [ "identificador" => "bib0400" "etiqueta" => "80" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2000" "volumen" => "27" "paginaInicial" => "2855" "paginaFinal" => "2859" "link" => array:1 [ …1] ] ] ] ] ] ] 80 => array:3 [ "identificador" => "bib0405" "etiqueta" => "81" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cyclosporin A in treatment of refractory adult polymyositis/dermatomyositis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Rheumatol" "fecha" => "2001" "volumen" => "28" "paginaInicial" => "2139" "link" => array:1 [ …1] ] ] ] ] ] ] 81 => array:3 [ "identificador" => "bib0410" "etiqueta" => "82" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence, predictors and associated outcomes of rhabdomyolysis after kidney transplantation" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ndt/gfp416" "Revista" => array:6 [ "tituloSerie" => "Nephrol Dial Transplant" "fecha" => "2009" "volumen" => "24" "paginaInicial" => "3861" "paginaFinal" => "3862" "link" => array:1 [ …1] ] ] ] ] ] ] 82 => array:3 [ "identificador" => "bib0415" "etiqueta" => "83" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rabdomiólisis secundaria a interacción de estatinas con macrólidos en un paciente con trasplante renal" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Nefrología" "fecha" => "2004" "volumen" => "4" "paginaInicial" => "382" "paginaFinal" => "383" ] ] ] ] ] ] 83 => array:3 [ "identificador" => "bib0420" "etiqueta" => "84" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic scleroderma (progressive systemic sclerosis), chemical diabetes mellitus, psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "1971" "volumen" => "103" "paginaInicial" => "682" "paginaFinal" => "685" "link" => array:1 [ …1] ] ] ] ] ] ] 84 => array:3 [ "identificador" => "bib0425" "etiqueta" => "85" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A case of severe form of psoriasis and systemic scleroderma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Vestn Dermatol Venerol" "fecha" => "1984" "volumen" => "5" "paginaInicial" => "48" "paginaFinal" => "49" "link" => array:1 [ …1] ] ] ] ] ] ] 85 => array:3 [ "identificador" => "bib0430" "etiqueta" => "86" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association of scleroderma and psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Vestn Dermatol Venerol" "fecha" => "1986" "volumen" => "6" "paginaInicial" => "66" "paginaFinal" => "68" "link" => array:1 [ …1] ] ] ] ] ] ] 86 => array:3 [ "identificador" => "bib0435" "etiqueta" => "87" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A rare association of systemic sclerosis with psoriasis vulgaris" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Dermatol" "fecha" => "2000" "volumen" => "27" "paginaInicial" => "346" "paginaFinal" => "349" "link" => array:1 [ …1] ] ] ] ] ] ] 87 => array:3 [ "identificador" => "bib0440" "etiqueta" => "88" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis and diffuse systemic sclerosis: a report of three patients" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2000" "volumen" => "39" "paginaInicial" => "213" "paginaFinal" => "215" ] ] ] ] ] ] 88 => array:3 [ "identificador" => "bib0445" "etiqueta" => "89" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Scleroderma and erosive polyarthritis: a disease entity?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "1982" "volumen" => "41" "paginaInicial" => "141" "paginaFinal" => "146" "link" => array:1 [ …1] ] ] ] ] ] ] 89 => array:3 [ "identificador" => "bib0450" "etiqueta" => "90" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "La sacroileite sclerodermica. Una entita anatomo-radiologica non nota" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Reumatismo" "fecha" => "1990" "volumen" => "42" "paginaInicial" => "117" "paginaFinal" => "126" ] ] ] ] ] ] 90 => array:3 [ "identificador" => "bib0455" "etiqueta" => "91" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic sclerosis could mask the presentation of psoriasis in a patient with symptomatic and bilateral sacroiliitis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Scand J Rheumatol" "fecha" => "2003" "volumen" => "32" "paginaInicial" => "186" "paginaFinal" => "188" "link" => array:1 [ …1] ] ] ] ] ] ] 91 => array:3 [ "identificador" => "bib0460" "etiqueta" => "92" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of scleroderma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2002" "volumen" => "138" "paginaInicial" => "99" "paginaFinal" => "105" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 92 => array:3 [ "identificador" => "bib0465" "etiqueta" => "93" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Calcium channel blockers intake and psoriasis: a case-control study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Acta Derm Venereol" "fecha" => "2001" …4 ] ] ] ] ] ] 93 => array:3 [ "identificador" => "bib0470" "etiqueta" => "94" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous reactions induced by calcium cannel blocker: high frequency of psoriasiform eruptions" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 94 => array:3 [ "identificador" => "bib0475" "etiqueta" => "95" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sartans, angiotensin II receptor antagonists, can induce psoriasis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 95 => array:3 [ "identificador" => "bib0480" "etiqueta" => "96" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis induced by losartan therapy: a case report and review of the literature" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ …3] ] ] ] ] ] 96 => array:3 [ "identificador" => "bib0485" "etiqueta" => "97" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.20676" "Revista" => array:6 [ …6] ] ] ] ] ] 97 => array:3 [ "identificador" => "bib0490" "etiqueta" => "98" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Kidney crisis in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 98 => array:3 [ "identificador" => "bib0495" "etiqueta" => "99" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis induced or aggravated by drugs" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.090227" "Revista" => array:6 [ …6] ] ] ] ] ] 99 => array:3 [ "identificador" => "bib0500" "etiqueta" => "100" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Triggered psoriasis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ …7] ] ] ] ] ] 100 => array:3 [ "identificador" => "bib0505" "etiqueta" => "101" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Double disease in rheumatology: coexistence of rheumatoid arthritis and psoriatic arthritis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 101 => array:3 [ "identificador" => "bib0510" "etiqueta" => "102" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2005.037424" "Revista" => array:6 [ …6] ] ] ] ] ] 102 => array:3 [ "identificador" => "bib0515" "etiqueta" => "103" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Coexistence of bullous rheumatoid neutrophilic dermatosis and palmoplantar pustulosis in a patient with rheumatoid arthritis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-4632.2009.04254.x" "Revista" => array:6 [ …6] ] ] ] ] ] 103 => array:3 [ "identificador" => "bib0520" "etiqueta" => "104" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inflammatory polyarthritis in a patient with psoriasis: is it psoriatic arthritis or rheumatoid arthritis?" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3904/kjim.2010.25.2.224" "Revista" => array:6 [ …6] ] ] ] ] ] 104 => array:3 [ "identificador" => "bib0525" "etiqueta" => "105" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1515/CCLM.2007.027" "Revista" => array:6 [ …6] ] ] ] ] ] 105 => array:3 [ "identificador" => "bib0530" "etiqueta" => "106" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2005.040998" "Revista" => array:6 [ …6] ] ] ] ] ] 106 => array:3 [ "identificador" => "bib0535" "etiqueta" => "107" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriatic arthritis: what the dermatologist needs to know, part 1" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 107 => array:3 [ "identificador" => "bib0540" "etiqueta" => "108" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Classification criteria for psoriatic arthritis: development of new criteria from a large international study" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.21972" "Revista" => array:6 [ …6] ] ] ] ] ] 108 => array:3 [ "identificador" => "bib0545" "etiqueta" => "109" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.21233" "Revista" => array:6 [ …6] ] ] ] ] ] 109 => array:3 [ "identificador" => "bib0550" "etiqueta" => "110" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/ar1724" "Revista" => array:6 [ …6] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010200000007/v1_201304241231/S1578219011000412/v1_201304241231/en/main.assets" "Apartado" => array:4 [ "identificador" => "6150" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Review" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010200000007/v1_201304241231/S1578219011000412/v1_201304241231/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219011000412?idApp=UINPBA000044" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 16 | 19 | 35 |
2024 Octubre | 159 | 70 | 229 |
2024 Septiembre | 146 | 70 | 216 |
2024 Agosto | 185 | 75 | 260 |
2024 Julio | 233 | 59 | 292 |
2024 Junio | 168 | 67 | 235 |
2024 Mayo | 163 | 67 | 230 |
2024 Abril | 137 | 48 | 185 |
2024 Marzo | 138 | 52 | 190 |
2024 Febrero | 170 | 47 | 217 |
2024 Enero | 268 | 69 | 337 |
2023 Diciembre | 166 | 39 | 205 |
2023 Noviembre | 172 | 53 | 225 |
2023 Octubre | 158 | 55 | 213 |
2023 Septiembre | 141 | 33 | 174 |
2023 Agosto | 126 | 31 | 157 |
2023 Julio | 146 | 66 | 212 |
2023 Junio | 133 | 36 | 169 |
2023 Mayo | 144 | 51 | 195 |
2023 Abril | 109 | 44 | 153 |
2023 Marzo | 164 | 56 | 220 |
2023 Febrero | 75 | 35 | 110 |
2023 Enero | 54 | 41 | 95 |
2022 Diciembre | 77 | 57 | 134 |
2022 Noviembre | 41 | 41 | 82 |
2022 Octubre | 40 | 36 | 76 |
2022 Septiembre | 37 | 36 | 73 |
2022 Agosto | 29 | 31 | 60 |
2022 Julio | 39 | 34 | 73 |
2022 Junio | 57 | 43 | 100 |
2022 Mayo | 80 | 46 | 126 |
2022 Abril | 77 | 51 | 128 |
2022 Marzo | 129 | 74 | 203 |
2022 Febrero | 89 | 40 | 129 |
2022 Enero | 80 | 66 | 146 |
2021 Diciembre | 67 | 66 | 133 |
2021 Noviembre | 58 | 61 | 119 |
2021 Octubre | 70 | 72 | 142 |
2021 Septiembre | 62 | 48 | 110 |
2021 Agosto | 49 | 89 | 138 |
2021 Julio | 65 | 66 | 131 |
2021 Junio | 69 | 45 | 114 |
2021 Mayo | 65 | 43 | 108 |
2021 Abril | 174 | 82 | 256 |
2021 Marzo | 96 | 36 | 132 |
2021 Febrero | 85 | 43 | 128 |
2021 Enero | 69 | 47 | 116 |
2020 Diciembre | 52 | 33 | 85 |
2020 Noviembre | 60 | 35 | 95 |
2020 Octubre | 65 | 30 | 95 |
2020 Septiembre | 65 | 25 | 90 |
2020 Agosto | 54 | 49 | 103 |
2020 Julio | 52 | 21 | 73 |
2020 Junio | 52 | 46 | 98 |
2020 Mayo | 65 | 49 | 114 |
2020 Abril | 54 | 40 | 94 |
2020 Marzo | 38 | 60 | 98 |
2020 Febrero | 4 | 31 | 35 |
2020 Enero | 0 | 33 | 33 |
2019 Diciembre | 0 | 23 | 23 |
2019 Noviembre | 0 | 20 | 20 |
2019 Octubre | 0 | 21 | 21 |
2019 Septiembre | 0 | 31 | 31 |
2019 Agosto | 0 | 24 | 24 |
2019 Julio | 0 | 39 | 39 |
2019 Junio | 0 | 54 | 54 |
2019 Mayo | 0 | 156 | 156 |
2019 Abril | 0 | 84 | 84 |
2019 Marzo | 2 | 28 | 30 |
2019 Febrero | 0 | 37 | 37 |
2019 Enero | 0 | 4 | 4 |
2018 Diciembre | 1 | 13 | 14 |
2018 Noviembre | 1 | 5 | 6 |
2018 Septiembre | 2 | 9 | 11 |
2018 Agosto | 0 | 24 | 24 |
2018 Julio | 0 | 19 | 19 |
2018 Junio | 0 | 16 | 16 |
2018 Mayo | 0 | 30 | 30 |
2018 Abril | 0 | 13 | 13 |
2018 Marzo | 3 | 13 | 16 |
2018 Febrero | 349 | 19 | 368 |
2018 Enero | 302 | 23 | 325 |
2017 Diciembre | 344 | 32 | 376 |
2017 Noviembre | 196 | 29 | 225 |
2017 Octubre | 197 | 19 | 216 |
2017 Septiembre | 142 | 20 | 162 |
2017 Agosto | 107 | 13 | 120 |
2017 Julio | 115 | 13 | 128 |
2017 Junio | 146 | 15 | 161 |
2017 Mayo | 131 | 26 | 157 |
2017 Abril | 125 | 16 | 141 |
2017 Marzo | 145 | 38 | 183 |
2017 Febrero | 351 | 10 | 361 |
2017 Enero | 112 | 17 | 129 |
2016 Diciembre | 130 | 16 | 146 |
2016 Noviembre | 140 | 8 | 148 |
2016 Octubre | 141 | 16 | 157 |
2016 Septiembre | 231 | 30 | 261 |
2016 Agosto | 120 | 26 | 146 |
2016 Julio | 81 | 17 | 98 |
2016 Junio | 9 | 19 | 28 |
2016 Mayo | 5 | 10 | 15 |
2016 Abril | 4 | 5 | 9 |
2016 Marzo | 9 | 2 | 11 |
2016 Febrero | 9 | 2 | 11 |
2016 Enero | 8 | 2 | 10 |
2015 Diciembre | 9 | 1 | 10 |
2015 Noviembre | 7 | 10 | 17 |
2015 Octubre | 17 | 3 | 20 |
2015 Septiembre | 5 | 3 | 8 |
2015 Agosto | 12 | 1 | 13 |
2015 Julio | 189 | 16 | 205 |
2015 Junio | 149 | 17 | 166 |
2015 Mayo | 171 | 20 | 191 |
2015 Abril | 159 | 8 | 167 |
2015 Marzo | 117 | 7 | 124 |
2015 Febrero | 114 | 9 | 123 |
2015 Enero | 139 | 11 | 150 |
2014 Diciembre | 105 | 19 | 124 |
2014 Noviembre | 81 | 10 | 91 |
2014 Octubre | 102 | 14 | 116 |
2014 Septiembre | 82 | 13 | 95 |
2014 Agosto | 92 | 18 | 110 |
2014 Julio | 101 | 22 | 123 |
2014 Junio | 116 | 12 | 128 |
2014 Mayo | 119 | 10 | 129 |
2014 Abril | 113 | 14 | 127 |
2014 Marzo | 103 | 28 | 131 |
2014 Febrero | 64 | 37 | 101 |
2014 Enero | 92 | 17 | 109 |
2013 Diciembre | 80 | 17 | 97 |
2013 Noviembre | 72 | 28 | 100 |
2013 Octubre | 66 | 24 | 90 |
2013 Septiembre | 45 | 27 | 72 |
2013 Agosto | 10 | 8 | 18 |
2013 Julio | 9 | 36 | 45 |
2013 Junio | 10 | 23 | 33 |
2013 Mayo | 12 | 29 | 41 |
2013 Abril | 10 | 24 | 34 |
2013 Marzo | 11 | 14 | 25 |
2013 Febrero | 27 | 10 | 37 |
2013 Enero | 43 | 8 | 51 |
2012 Diciembre | 19 | 6 | 25 |
2012 Noviembre | 1 | 5 | 6 |
2012 Septiembre | 1 | 0 | 1 |
2012 Julio | 1 | 0 | 1 |